- Home
- VGI vs TIL Comparison
VGI vs TIL Comparison
Compare VGI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- TIL
- Stock Information
- Founded
- VGI 2012
- TIL 2018
- Country
- VGI United States
- TIL United States
- Employees
- VGI N/A
- TIL N/A
- Industry
- VGI Investment Managers
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- VGI Finance
- TIL Health Care
- Exchange
- VGI Nasdaq
- TIL Nasdaq
- Market Cap
- VGI 89.7M
- TIL 177.1M
- IPO Year
- VGI N/A
- TIL 2021
- Fundamental
- Price
- VGI $7.98
- TIL $21.03
- Analyst Decision
- VGI
- TIL Buy
- Analyst Count
- VGI 0
- TIL 6
- Target Price
- VGI N/A
- TIL $120.50
- AVG Volume (30 Days)
- VGI 46.0K
- TIL 150.1K
- Earning Date
- VGI 01-01-0001
- TIL 11-12-2025
- Dividend Yield
- VGI 12.66%
- TIL N/A
- EPS Growth
- VGI N/A
- TIL N/A
- EPS
- VGI N/A
- TIL N/A
- Revenue
- VGI N/A
- TIL N/A
- Revenue This Year
- VGI N/A
- TIL N/A
- Revenue Next Year
- VGI N/A
- TIL N/A
- P/E Ratio
- VGI N/A
- TIL N/A
- Revenue Growth
- VGI N/A
- TIL N/A
- 52 Week Low
- VGI $6.68
- TIL $10.80
- 52 Week High
- VGI $7.99
- TIL $73.69
- Technical
- Relative Strength Index (RSI)
- VGI 50.10
- TIL 37.54
- Support Level
- VGI $7.96
- TIL $20.11
- Resistance Level
- VGI $8.04
- TIL $25.89
- Average True Range (ATR)
- VGI 0.05
- TIL 2.57
- MACD
- VGI -0.01
- TIL -0.69
- Stochastic Oscillator
- VGI 15.38
- TIL 6.70
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.